Back to results
US 12,291,708 B2Granted
Oral delivery of antisense conjugates targeting PCSK9
AssigneeCiVi Biopharma, Inc.
InventorsHenrik Oerum, Stewart Alwyn Noble, Charles Lester Shear
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.
Claims14
A pharmaceutical composition for oral delivery to a subject comprising
- (i) an antisense oligonucleotide of formula I (SEQ ID NO:
- 19)
- and,
- (ii) N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) or a salt thereof,
- in a tablet or capsule comprising a pH-sensitive enteric coating, wherein the pharmaceutical composition is formulated to release the antisense oligonucleotide of formula I in the subject's small intestine following oral administration.
2 more elements
Dependencies are inferred from the claim text.